Roche sues over blockbuster cancer drug as key patent protection expires

In a New Jersey lawsuit, Henlius and Organon are accused of submitting an aBLA for a biosimilar that infringes two dozen patents.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

UK govt sets sights on being AI drug discovery ‘world leader’

13 June 2025 Government unveils £8M OpenBind consortium to lead in AI drug discovery | Project to build world’s largest drug–protein dataset | Backed by new Sovereign AI Unit, Consortium will be based at national synchrotron facility in Oxfordshire.

Americas

Takeda, Pfizer, and Sumitomo sue to protect $379m Orgovyx revenue

20 March 2025 Trio files multiple patent infringement lawsuits to protect blockbuster prostate cancer drug | Latest suits target Hetero and Aizant, following similar actions against Apotex, BDR Pharmaceuticals, and CIPLA.

More features

Is AI emerging as the ‘fourth party’ solving billion-dollar disputes?

Why AI is changing the patent rules faster than anyone can keep up

The hidden code in life sciences deals

LSPN panel unpacks critical IP risks in deal-making

A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order

Less is more: patent lawyers flip the script after Amgen

‘Doing more with less’: In-house counsel on budgets and strategy

End of the ‘Death Squad’? Squires puts PTAB on trial

Roche sues over blockbuster cancer drug as key patent protection expires

More on this story

Editor's picks

Editor's picks

More features